title: Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
abstract: BACKGROUND
  The role of second-line therapy in metastatic pancreatic cancer is not clear. In this study, we aimed to explore the second-line efficiency of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer who have received gemcitabine-based first-line therapy.
  
  
  METHODS
  We retrospectively evaluated 47 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine-based first-line regimens. Treatment consisted of oxaliplatin 130 mg/m2 and capecitabine 1000 mg/m2 twice daily with a 3 week interval, until unacceptable toxicity or disease progression.
  
  
  RESULTS
  Median number of cycles was 4 (range, 2-10). The overall disease control rate was 38.3%. The median overall survival and progression-free survival from the start of second-line therapy were 23 weeks (95%CI: 16.6-29.5 weeks) and 12 weeks (95%CI: 9.8-14.4 weeks), respectively. The most common grade 3-4 toxicities were nausea, vomiting and hematologic side effects.
  
  
  CONCLUSIONS
  Our result suggests that the combination of capecitabine and oxaliplatin was tolerated with manageable toxicity and showed encouraging activity as second-line treatment of advanced or metastatic pancreatic cancer patients with ECOG performance status 0-2.
authors.affiliation: Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey E-mail : dralaca2000@yahoo.com.
authors.forename: Ibrahim Vedat
authors.initials: IV
authors.lastname: Bayoglu
authors.forename: Umut
authors.initials: U
authors.lastname: Varol
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yildiz
authors.forename: Ugur
authors.initials: U
authors.lastname: Muslu
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Kucukzeybek
authors.forename: Murat
authors.initials: M
authors.lastname: Akyol
authors.forename: Lutfiye
authors.initials: L
authors.lastname: Demir
authors.forename: Ahmet
authors.initials: A
authors.lastname: Dirican
authors.forename: Suna
authors.initials: S
authors.lastname: Cokmert
authors.forename: Yasar
authors.initials: Y
authors.lastname: Yildiz
authors.forename: Bulent
authors.initials: B
authors.lastname: Karabulut
authors.forename: Ruchan
authors.initials: R
authors.lastname: Uslu
authors.forename: Mustafa Oktay
authors.initials: MO
authors.lastname: Tarhan
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010071:Oxaloacetates; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D014839:Vomiting / Q000139:chemically induced; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil; D000093542:Gemcitabine